A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated waldenstrom's macroglobulinemia (WM).

被引：9
|
作者：
Rossi, Jean-Francois
Moreaux, Jerome
Rose, Mikaelle
Picard, Marie
Ythier, Arnaud
Rossier, Ciara
Sievers, Eric
Klein, Bernard
机构：
[1] Univ Hosp, Unit Cellular & Gene Therapy, Montpellier, France
[2] Serono Int, Geneva, Switzerland
[3] Zymogenet Inc, Seattle, WA 98105 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3578.3578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3578
引用
下载
收藏
页码：1022A / 1022A
页数：1
相关论文
共 50 条
  • [1] A phase I/II study of TACI-Ig to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma or active previously-treated Waldenstrom's macroglobulinemia.
    Rossi, JF
    Borghini-Fuhrer, I
    Moreaux, J
    Requirand, G
    Bouseida, S
    Picard, M
    Ythier, A
    Sievers, E
    Klein, B
    BLOOD, 2005, 106 (11) : 721A - 721A
  • [2] A phase I/II study of atacicept, an inhibitor of APRIL and BLyS, in multiple myeloma (MM) and waldenstrom's macroglobulinemia (WM)
    Rossi, J. F.
    Moreaux, J.
    Rose, M.
    Picard, M.
    Ythier, A.
    Hausman, D.
    Klein, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 153 - 153
  • [3] Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenstrom's Macroglobulinemia
    Rossi, Jean-Francois
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 136 - 138
  • [4] Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study
    Rossi, J-F
    Moreaux, J.
    Hose, D.
    Requirand, G.
    Rose, M.
    Rouille, V.
    Nestorov, I.
    Mordenti, G.
    Goldschmidt, H.
    Ythier, A.
    Klein, B.
    BRITISH JOURNAL OF CANCER, 2009, 101 (07) : 1051 - 1058
  • [5] A phase Ib trial of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed B-cell chronic lymphocytic leukemia (B-CLL)
    Kofler, D. M.
    Elter, T.
    Gianella-Borradori, A.
    Busby, S.
    Wendtner, C. M.
    Hallek, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
    J-F Rossi
    J Moreaux
    D Hose
    G Requirand
    M Rose
    V Rouillé
    I Nestorov
    G Mordenti
    H Goldschmidt
    A Ythier
    B Klein
    British Journal of Cancer, 2009, 101 : 1051 - 1058
  • [7] Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenstrom's macroglobulinemia (WM).
    Thomas, Sheeba K.
    Melendez, A. Georgina
    Feng, Lei
    Wang, Michael
    Neelapu, Sattva Swarup
    Shah, Jatin J.
    Orlowski, Robert Z.
    Weber, Donna M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM.
    Chen, C. I.
    Kouroukis, T.
    White, D.
    Voralia, M.
    Stadtmauer, E.
    Wright, J.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 432S - 432S
  • [9] A PHASE II STUDY OF THE COMBINATION OF OFATUMUMAB WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA
    Gavriatopoulou, M.
    Roussou, M.
    Fotiou, D.
    Ziogas, D.
    Terpos, E.
    Kalapanida, D.
    Kafantari, E.
    Papathoma, A.
    Spyropoulou-Vlachou, M.
    Dimopoulos, M. A.
    Kastritis, E.
    HAEMATOLOGICA, 2016, 101 : 478 - 478
  • [10] Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)
    Chen, CI
    White, D
    Kouroukis, CT
    Stewart, AK
    Howson-Jan, K
    Larratt, L
    Powers, J
    Eisenhauer, E
    BLOOD, 2004, 104 (11) : 896A - 896A
12345